Prescribing facts for lecanemab features a boxed warning about opportunity risks related to ARIA. Correct use tips focus on ways to minimize ARIA chance, as does AAN direction. The extension research also evaluated CLARITY AD participants who experienced a delayed start out (those who switched from placebo to lecanemab once https://edeni208enw7.blogmazing.com/profile